Nov 28, 2011
SuppreMol starts SM101 dosing in the context of SMILE study

Aug 02, 2011
SuppreMol employs Protagen biomarkers in SLE study

Jul 11, 2011
SuppreMol initiates Phase IIa clinical trial in Systemic Lupus Erythematosus (SLE) with its lead candidate SM101

January 9-11, 2012
Biotech Showcase 2012, San Francisco, CA, USA

January 9-12, 2012
30th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, USA

January 9-13, 2012
PEP TALK, San Diego, CA, USA

February 26-28, 2012
10th Annual BioPartnering North America, Vancouver, Canada

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol GmbH is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

At present, SuppreMol develops drug candidates for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis and Psoriasis. Its lead product SM101 already is in clinical development.

The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry and is located in Martinsried near Munich, Germany.